Drug intelligence / Profile preview

BG-201

Development stage: Preclinical
Lead developer: BlissGene Therapeutics
Modality: Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

BG-201 is a gene therapy candidate currently in the discovery phase, developed by BlissGene Therapeutics for the treatment of anxiety disorders. The therapeutic approach utilizes proprietary brain-selective lipid nanoparticles (LNPs) to deliver genetic material directly to the central nervous system. This genetic cargo is designed to modulate synaptic transmission, with the objective of promoting emotional equilibrium and reducing hyperarousal states in chronic anxiety models. The development of BG-201 is part of BlissGene's broader strategy to translate genetic insights from individuals with rare mutations conferring resilience to pain and emotional distress into precision medicines for neurological and psychiatric conditions.

Beyond the preview

Go deeper on BG-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-201.

Explore the full profile